Pathophysiological Subtyping of Abnormalities in Cocaine Dependence - 9

This study has been completed.

First Received on April 18, 2001. Last Updated on June 23, 2005 History of Changes

Sponsor:	National Institute on Drug Abuse (NIDA)
Collaborator:	New York MDRU
Information provided by:	National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov Identifier:	NCT00015275

Purpose

The purpose of this study is to define pathophysiological subtypes of abnormalities in subjects with cocaine dependence.

Condition	Intervention	Phase
Cocaine-Related Disorders Substance-Related Disorders	Behavioral: Cocaine-Related Disorders	Phase IV

Study Type:	Interventional
Study Design:	Masking: Open Label Primary Purpose: Diagnostic
Official Title:	Pathophysiological Subtyping of Abnormalities in Cocaine Dependence

Resource links provided by NLM:

MedlinePlus related topics: Drug Abuse

Drug Information available for: Cocaine hydrochloride

U.S. FDA Resources

Further study details as provided by National Institute on Drug Abuse (NIDA):

Primary Outcome Measures:

Identification of homogenous subgroups within total population of cocaine dependent adults

Estimated Enrollment:

Detailed Description:

The objective of this study is to define subgroups of patients with differential treatment outcome on the basis of differential baseline electrophysiological clusters.

Eligibility

Genders Eligible for Study:	Male
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Cocaine dependence. Seeking residential treatment.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00015275

Locations

United States, New York
New York MDRU
New York, New York, United States, 10010

Sponsors and Collaborators

National Institute on Drug Abuse (NIDA)

New York MDRU

Investigators

Principal Investigator:

John Rotrosen, M.D.

New York MDRU

More Information

No publications provided

ClinicalTrials.gov Identifier:	NCT00015275 History of Changes
Other Study ID Numbers:	NIDA-5-0013-9, Y01-5-0013-9
Study First Received:	April 18, 2001
Last Updated:	June 23, 2005
Health Authority:	United States: Federal Government

Additional relevant MeSH terms:

Congenital Abnormalities
Cocaine-Related Disorders
Substance-Related Disorders
Mental Disorders
Cocaine
Vasoconstrictor Agents
Cardiovascular Agents
Therapeutic Uses
Pharmacologic Actions
Dopamine Uptake Inhibitors
Dopamine Agents

Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Uptake Inhibitors
Physiological Effects of Drugs
Anesthetics, Local
Anesthetics
Central Nervous System Depressants
Sensory System Agents
Peripheral Nervous System Agents
Central Nervous System Agents

ClinicalTrials.gov processed this record on February 12, 2012